Fda

©Getty Images - David Trood

FDA slams Delta-8 THC sellers over claims

By Hank Schultz

FDA came down hard on purveyors of Delta-8 THC and CBD products that were making disease claims on the substances. The Agency also reiterated the reasons it believes Delta-8 is not a suitable ingredient for products marketed as supplements.

Getty Images / VioletaStoimenova

Stress: What can you claim on a product label?

By Danielle Masterson

According to the 2021 CRN Consumer Survey on Dietary Supplements, 16% of dietary supplement users said they turned to supplements for mental health support (e.g. anxiety, depression, stress management).

Getty Images / Adie bush

Poll finds many parents don't understand CBD

By Danielle Masterson

Despite the wide availability of CBD in its various forms—oil, topical ointments, tinctures, vaping and edibles— a recent poll shows parents are misinformed on CBD.

Dr Cara Welch speaking with NutraIngredients-USA in 2015

Cara Welch named permanent director of ODSP at FDA

By Stephen Daniells

The US Food and Drug Administration has announced that Dr Cara Welch will be the new permanent director of its Office of Dietary Supplement Programs. The announcement was welcomed by industry trade groups.

Schisandra chinensis or five-flavor berry on a branch. The berries possess all five basic flavors in Chinese herbal medicine: salty, sweet, sour, pungent (spicy), and bitter.   Image © Geshas / Getty Images

In memory of Ben Zaricor, 1947-2022

Fmali v Heckler: The landmark herb case that changed the industry

By Stephen Daniells

It started with ten-speed bicycles and ended with an Appeals Court decision in 1983 that changed the herb industry and knocked FDA down a peg. Four decades later, it’s time to shine the spotlight on this game-changing court case.

NPA Fabricant on CBD, NDIs, FDA resuming inspections

NPA Fabricant on CBD, NDIs, FDA resuming inspections

By Stephen Daniells

FDA has stated it is making ‘substantial progress’ with CBD, and a new enforcement guidance could be very significant for the industry, said NPA’s Dr Daniel Fabricant, but he said the Agency needs to ‘get in the game’ for NDIs.

CBD firm CV Sciences reports 11% rise in sales

CBD firm CV Sciences reports 11% rise in sales

By Danielle Masterson

One of the pioneers of the space topped $53 million in annual revenue, but also recorded a loss as the founders cashed out. The firm also said regulatory uncertainty has increased competition as numerous small brands crowd into the field.

Use of aromatase inhibitor forms basis of warning letter

Use of aromatase inhibitor forms basis of warning letter

By Hank Schultz

A recently posted warning letter cites a New York company for the presence of an aromatase inhibitor in one of its dietary supplements. This class of chemicals is popular with strength trainers for its purported ability to suppress estrogen levels.

'The substance is well known, under surveillance and forbidden,' a spokesperson for the Austrian food agency says. ©iStock.com/Pogonici

Summer of DMAA: Spate of imports blocked in EU

By Annie Harrison-Dunn

There have been several cases of the dangerous stimulant 1,3-dimethylamylamine (DMAA) being blocked at the EU borders over the last few months. But what is being done to stem the flow of the outlawed ingredient?

Will the market or FDA deliver the final blow for DMAA?

Will the market or FDA deliver the final blow for DMAA?

By Stephen Daniells

There is a moment at the end of the legendary computer game, Mortal Kombat, where you have just beaten seven shades of something out of your opponent and all that is left is one final blow. ‘Finish him!’ says the game, and you ready your thumbs for the coup...

Credit where credit is due: FDA activity is a good thing

FDA's enforcement deserves loud applause

By Stephen Daniells

A flurry of seizures, criminal charges, and warning letters shows that FDA is increasing it enforcement of dietary supplement regulations. Good for FDA and good for industry!

A transatlantic view of regulations and health claims

A transatlantic view of regulations and health claims

By Stephen Daniells

Should the FDA work to be more like EFSA? Speaking at the NutraIngredients Health Claims 2010 conference Andrew Shao said the two organisations are already very similar in the way they review scientific claims.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers